TOP HEADLINES

Special Report

  • Top 10 Phase III disasters of 2014

    Welcome to the hall of shame, where blockbuster drug projections go to die. Here you'll find some drugs that clearly should never have wound up in Phase III to begin with, a few that were actually steered back to the clinic in a doomed attempt to mine something positive after wasting millions on clinical trials and a couple of notable exceptions that may have helped advance the field by exploring the outer limits of new drug technology. Read more >>

Roche blueprints a sprawling $1.8B R&D complex for pRED

They're building a new home for John Reed and Roche's pRED research group in Basel--and the pharma giant is thinking big. Roche said today that it is committing $1.8 billion to build a new research center in Switzerland that will encompass four new office and lab buildings to house 1,900 R&D staffers.

Regulus soars on promising--but early--results for its hep C contender

Regulus Therapeutics, at work on a microRNA approach to hepatitis C, watched its shares skyrocket on positive early data for its lead candidate, which significantly reduced viral loads with a single dose.

Activist investor joins the Amgen breakup crusade, and shareholders are listening

Hedge fund manager Daniel Loeb is lending his voice to the chorus of investors who believe Amgen would do better as two companies. And his firm, Third Point, has upped its stake in the Big Biotech, giving him a bigger stage from which to pressure executives.

J&J gives the Ebola vaccine push a $200M boost

With several players now in the race toward a vaccine for Ebola, Johnson & Johnson says it is ramping up development efforts toward its own program, devoting $200 million to the cause.

Proteon banks $61M in a down-sized IPO as it moves on without Novartis

Proteon Therapeutics priced its IPO below its expected range, clearing $61 million to pay the way for its investigational vascular drug.

MORE NEWS

From Our Sister Sites

FierceVaccines

To help show Americans just how important its flu vaccines are, Novartis has teamed up with entertainer Nick Cannon, who's advising consumers to prepare for flu season by getting their shots and stocking up on the Swiss pharma's over-the-counter remedy, Theraflu.

FierceVaccines

GlaxoSmithKline's vaccines unit will be getting a new look come next year, when it's expected to absorb the bulk of Novartis' vaccines lineup it bought for $7.1 billion back in April. It'll have some new management, too, with Moncef Slaoui in the chairman's role. And judging from the pharma giant's Q3 results, some change for the unit could be a good thing.